Zinzino AB reported its preliminary sales results for the first quarter of 2026. Group revenue in the first quarter reached $96.8 million, a 26% year-over-year increase, while the Faun Pharma external sales division fell from approximately $751,000 to approximately $698,000. Zinzino March 2026 revenue, in particular, increased 29% year-over-year and reached $36.2 million.
South America, which includes Peru and Colombia, posted the highest year-over-year first quarter market improvement, with 413% growth. North America, which includes the US, Mexico and Canada, also reported significant momentum, with a 71% growth rate over the same quarter of 2025.
All markets, with the exception of East Europe (Czech Republic, Slovakia, Hungary, Poland, Romania), experienced positive market growth.
